INTRODUCTION
Evidence that bipolar disorder (BD) in adults is associated with broad neurocognitive impairment across several domains has accumulated in the literature in the past two decades.
1,2 These findings have been synthesized in several meta-analyses 3-5 that confirmed that euthymic adults with BD have most pronounced deficits (of moderate to large effect sizes) in attention, verbal memory, and executive function. Furthermore, a large individual patient meta-analysis confirmed that euthymic adults with BD exhibit cognitive impairment encompassing several domains. 6 Nevertheless, this effort found smaller effect sizes in comparison to previous meta-analyses, perhaps due to a more accurate adjustment for potential confounders and the inclusion of unpublished datasets. 6 BD has been increasingly diagnosed in pediatric age groups, with an estimated pooled prevalence rate of 1.8% in general population surveys. 7 In addition, a significant proportion of adults with BD have onset of illness before the age of 18. 8,9 Patients with early onset of illness may have worse outcomes including but not limited to fewer days of euthymia and greater functional impairment, which may hamper academic achievements.
9-12
Cognitive impairment is thought to be a main mediator of disability and functional impairment in BD. 2, 13 Evidence indicates that cognitive impairment may be evident in firstepisode BD. 14 A previous systematic review 15 and two meta-analyses 16, 17 suggested that cognitive impairment in pediatric BD is mainly present in verbal learning, processing speed, and executive function domain. However, these analyses included individuals with BD during different mood states, and the largest available meta-analysis included 12 unique studies (N=374). 17 Since the publication of those previous systematic reviews and metaanalyses, several new original studies provided data on cognitive function in euthymic youths with BD. [18] [19] [20] [21] However, different clinical characteristics of samples may lead to heterogeneity M A N U S C R I P T Therefore, a systematic review and meta-analysis of studies that had assessed cognitive impairment in euthymic youths with BD compared to healthy controls was performed. We expected a high degree of heterogeneity across studies in part due to differences in sample characteristics (for example, duration of illness, comorbid ADHD, and medication status) as well as differences in neuropsychological measures. 23 Thus, we also aimed to explore potential sources of heterogeneity.
A C C E P T E D

METHOD
This study comprised a meta-analysis of studies comparing neurocognitive function in euthymic youths with BD to healthy controls. We complied with the Preferred Reported
Items for Systematic Reviews and Meta-analysis (PRISMA) statement, and followed an a priori defined yet unpublished protocol. 24 The literature search, title/abstract screening, final decision on eligibility after full-text review, and data extraction were independently performed by at least two investigators (L.R.O., A.M.O.V., and H.L.K.). Disagreements were resolved through consensus. If a consensus could not be achieved, the decision was made independently by a third investigator (C.A.K.).
Search Strategy
A systematic search was conducted in the EMBASE, PubMed/MEDLINE, and criteria for BD, and a comparison sample of healthy controls (HCs). In addition, the diagnosis of BD had to be established through a validated structured/semi-structured diagnostic interview. For this systematic review, we considered studies that had measured cognitive domains according to standard tests and/or batteries (vide infra). Neurocognitive function has been heuristically subdivided into "hot" (i.e., emotion-laden) and "cold" (i.e., emotionindependent) cognition. 28, 29 For the purposes of this systematic review, we had solely included studies measuring "cold" cognition because this dimension has been more consistently related to clinical outcomes (e.g., functional status). 15 We applied the following exclusion criteria: (1) studies that did not diagnose BD by means of a structured diagnostic interview; (2) meeting abstracts; (3) studies published in other languages (i.e., not specified above); (4) studies that included participants from other age groups (unless data were reported separately for youths); (5) investigations that included participants with BD in an acute mood episode or otherwise clinically unstable; (6) studies that did not include an HC group.
Data Extraction
We extracted the means ± standard deviation (SD) of each neuropsychological test score or the appropriate reported effect size estimate. In addition to meta-analysis of individual tests, we also grouped tests according to cognitive domains based on the National
Institute of Mental Health-MATRICS (Measurement and Treatment Research to Improve
Outcome in Schizophrenia) with slight modifications due to available data from tests not included in this initiative (Table S1 , available online). 30, 31 We also extracted the following data whenever available: (1) First author; (2) Publication Year; (3) sample size; (4) gender for participants with BD and no comorbid mental disorders whenever a study provided these data.
Statistical Analysis
Because studies used different measurement methods, standardized mean difference estimates of difference in test scores were used as effect size (ES) estimates utilizing Hedge's g, which provides an unbiased ES adjusted for small sample sizes. 38 The 95% CI was also computed. 39 An ES of 0.2 was considered low, 0.5 moderate, and 0.8 large. 40 The ES of each cognitive domain represents the average of the ES estimates derived from each of its pertinent neuropsychological measures. 41 We also calculated a global cognition measure by averaging the ES from each cognitive domain, when three or more domains were assessed in the same study. 41 This composite measure aimed to provide a broad estimate of overall cognitive function. At least three independent datasets had to be available to estimate a summary ES (for both individual tests and cognitive domains).
Studies with statistically non-significant (i.e. negative) results are less likely than studies with positive results of being published. 42, 43 To account for significant publication bias, we inspected a funnel plot graph for asymmetry and calculated the Egger's test. 44 We assessed the heterogeneity across studies using the Cochran Q test, a weighted sum of the squares of the deviations of individual study ES estimates from the overall
estimate. In addition, heterogeneity across studies was quantified with the I 2 statistic, which in brief indicates the percentage of total variation across several studies due to heterogeneity, and it is considered moderate when between 50-75%, and high when greater than 75%. 45 We anticipated a high degree of heterogeneity. Therefore, we pooled ES from several studies according to the inverse variance method of accounting for random effects. Random-effects modelling assumes a genuine diversity across studies and incorporates a between-study variance into the calculations. 39 We explored potential sources of heterogeneity across studies in each cognitive domain with either subgroup or random-effects meta-regression analyses. We considered the following variables in univariate meta-regression analyses: sample size, mean age of BD group, mean age of the HC group, differences in mean age (BD group minus HC group), % of females in the BD group, % of females in the HC group, difference in % of females (BD group minus HC group), mean IQ of the BD group, mean IQ of the HC group, difference in mean IQ (BD group minus HC group), % of participants on lithium, % of participants on anticonvulsants, % of participants on antipsychotics. Studies were weighted in such a way that investigations with more precise parameters (indicated by sample size and 95% CI) had more influence in meta-regression analyses. 46 A covariate was investigated in metaregression analyses when at least five independent datasets provided data on the potential moderator. We performed a subgroup analysis based on the criteria of euthymia employed in each study. For the purposes of these analyses, we classified each study based on a stringent definition of euthymia (i.e., euthymia as pre-defined based on scores in standard symptom rating instruments). A non-stringent definition of euthymia was considered when at least one of the following were met: (1) mean scores of the Young Mania Rating Scale (YMRS) 47 < 12 and the Children's Depression Rating Scale-Revised (CDRS-R) 48 
RESULTS
Following the removal of duplicates, the title/abstracts of 1,909 unique references were screened for eligibility. A total of 1,675 references were excluded, while 234 full-text were retrieved and screened for eligibility. Finally, 24 original studies met inclusion criteria. [18] [19] [20] [21] [22] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] Figure 1 provides the PRISMA flowchart for study selection.
Characteristics of Included Studies
This systematic review and meta-analysis included 24 studies that provided data from 1,146 participants (510 youths with BD and 636 HCs). Across the 24 included studies, there were no differences in age (BD group: 13.62 ± 3.76; HC group: 13.29 ± 3.22, P = .12) and IQ scores (BD group: 103.58 ± 15.76; HC group: 104.64 ± 24.32, P = .44) between groups, while 12 studies followed an age-and gender-matched design. Table S2 (available online) provides a description of included studies.
Global Cognition
Seven studies provided evidence that youths with BD are significantly impaired in global cognition (Table 1) . There was no evidence of publication bias. Heterogeneity was
. Figure 2A provides the forest plot of this meta-analysis. Mean age of the BD group appeared to moderate this ES estimate, with older participants being more cognitively impaired. The frequency of current use of lithium and antipsychotics also moderated this outcome, where use of these medications appeared to impair this domain (Table S3 , available online). Subgroup analyses found that global cognition was impaired in studies that included youths with BD and comorbid anxiety disorders (with low heterogeneity) but not in those that included participants without comorbid anxiety disorders.
In addition, deficits in this domain were significant in studies that included youths with BD and co-morbid ADHD (with low heterogeneity) but not in those that included youths with BD without comorbid ADHD. Lastly, impairment in this domain was observed only in studies that considered the stringent criteria for euthymia albeit with high heterogeneity (Table S4, available online).
<Please insert Table 1 here>
Attention and Vigilance
Overall, attention and vigilance were not significantly impaired in youths with BD compared to HCs (Table 1 ; Figure 3 ). However, a moderate degree of heterogeneity was observed for this ES estimate. Meta-regression analyses suggested that the mean age and the percentage of female participants in the HC moderated this outcome. Furthermore, the frequency of current use of anticonvulsants and antipsychotics emerged as moderators of this outcome, with evidence suggesting that the use of these drugs could impair this cognitive domain (Table S3 , available online). Subgroup analyses suggest that this cognitive domain could be impaired in youths with BD in studies that considered the stringent criteria for euthymia (with low heterogeneity) but not in studies that considered other definitions (Table   S4 , available online). Furthermore, impairment in this domain was observed in studies that included youths with BD and comorbid anxiety disorders, but not studies that included only
participants with BD without this comorbidity (Table S4 , available online). Participants with BD were slightly impaired in the hit reaction time and the omission scores of the Continuous Performance Test-II (CPT-II). 69 These results suggest that youths with BD may have difficulties with sustained attention. Interestingly, heterogeneity for this ES estimates were low. In addition, results of the Go/Nogo tasks seem to confirm that youths with BD have deficient impulse control ( Table 1) .
Reasoning and Problem Solving
Youths with BD were not significantly impaired in reasoning and problem solving (Table 1 ; Figure 4 ). However, heterogeneity for this ES estimate was high. Meta-regression analyses indicated that the frequency of use of antipsychotics and anticonvulsants moderated this ES, with data suggesting that the use of these drugs could impair this domain (Table S3, available online).
Verbal Learning and Memory
Youths with BD were significantly impaired in verbal learning and memory compared to HCs, with a moderate ES ( Figure 2B ). Heterogeneity was large (Table 1 ). In studies that considered a stringent definition for euthymia, heterogeneity was low and a significant impairment was observed, whereas no significant effect was verified in studies that used other definitions of euthymia. Furthermore, impairment in this domain was observed in studies that included youths with BD and co-occurring ADHD (with low heterogeneity) but not in studies that included solely youths with BD without this comorbidity (Table S4, available online).
Working Memory
Our results indicate that pediatric BD is associated with large impairments in working memory (Table 1 ; Figure 2C ). Heterogeneity was moderate (I 2 =62%). However, it is noteworthy that results obtained with the Wechsler Intelligence Scale for Children (WISC)
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Heterogeneity was large in studies that included youths with BD and comorbid anxiety disorders, but low in studies that included youths with BD without this comorbidity (Table   S4 , available online).
Speed of Processing
Just three studies provided extractable data for the speed of processing domain.
22, 51, 65 Evidence suggests that youths with BD are not significantly impaired in this domain (Table 1 ; Figure 5 ).
Visual Learning and Memory
Youths with BD were significantly impaired in visual learning and memory (Table 1 ; Figure 2D ) with a moderate to large ES (Hedge's g = 0.78). In addition, heterogeneity was low.
Verbal Fluency
A single small study (N=40) investigated this cognitive domain by means of the Benton Controlled Oral Association Test, phonemic Fluency FAS (COWAT). 21, 70 No significant difference between euthymic adolescents with BD and age-and gender-matched controls was observed.
Power Analysis
A post hoc power analysis indicate that the meta-analysis of the attention and vigilance domain had adequate power to reject the null hypothesis considering a medium 'true' effect size, whereas the summary ES estimates for reasoning and problem solving and speed of processing had a low power to reject the null hypothesis considering a medium 'true' effect size (Table S5 , available online).
DISCUSSION
This meta-analysis provides evidence that euthymic pediatric patients with BD have M A N U S C R I P T A C C E P T E D Two recent meta-analyses indicate that global cognitive deficits are already evident in first-episode BD. 14, 72 However, these meta-analyses included only studies of adult samples.
Our results provide evidence that cognitive dysfunction encompassing several cognitive domains could already be evident in euthymic youths with BD.
Some limitations of our work deserve discussion. First, heterogeneity for several ES estimates was high. We explored potential sources of heterogeneity across studies with standard meta-regression and subgroup analyses. Results from meta-regressions should be cautiously interpreted due to the possibility of type I error. 73 We found evidence that the use of medications contributed to the heterogeneity of most ES estimates. In addition, metaregression analyses suggested that the frequency of use of lithium and antipsychotics may have a detrimental effect upon global cognition. Few studies have investigated the cognitive effects of those medications in youths with BD. A previous observational study found that mood stabilizers may adversely impact certain neurocognitive domains, while atypical antipsychotics had no significant effect on neurocognition. 74 Clearly our findings should be interpreted cautiously due to the inclusion of few studies in those analyses, and future prospective studies are needed to investigate the impact of mood stabilizing medications on cognition in pediatric samples with BD. In addition, it is possible that the effects observed in M A N U S C R I P T
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our exploratory analyses could be confounded by other clinical variable (e.g., youths with more severe BD could more likely require the use of mood stabilizing medications). We could not control for these covariates (e.g., length of illness, number of affective episodes) due to the fact that included studies did not consistently provide data. It is worthy to note that the definition of euthymia has varied across studies, which might have influenced some findings of our analyses. For example, most of the heterogeneity in the ES estimate of the verbal learning and memory domain appeared to be explained by the criterion of euthymia adopted by each study, with low heterogeneity for studies that used a more stringent definition of euthymia. Furthermore, our analyses suggest that co-morbid ADHD or anxiety disorders contributed to the heterogeneity of several estimates, and we found some indications that these co-occurring disorders may negatively impact some neurocognitive domains (e.g. global cognition and attention/vigilance). These suggestive findings add to emerging evidence that indicates that these comorbidities may have a deleterious impact on the course of pediatric BD. 75 Lastly, neuropsychological measures tapping into the cognitive domains varied across studies. This aspect may have contributed to heterogeneity of some estimates. For instance, whilst no significant differences emerged in the attention/vigilance domain, individual test meta-analyses (in the CPT-II and Go/Nogo tasks) suggested that youths with BD do display impaired attention and impulse control regulation.
Two previous quantitative analyses have included youths with BD across the spectrum of mood states. 16, 17 Our meta-analysis was restricted to the inclusion of euthymic pediatric participants with BD, thus allowing a more precise estimation of trait-related cognitive deficits. Furthermore, this updated meta-analysis included twice the number of studies compared to the largest previous meta-analysis. 17 This previous meta-analysis found broader cognitive impairments (with medium ES estimates) in youths with BD encompassing general cognitive ability, attention, executive control, working memory, visuospatial skills,
verbal fluency, verbal learning and memory, and visual memory domains. 17 However, the inclusion of participants in different mood states might have confounded their results as suggested by an exploratory moderator analysis performed by the authors. 17 Thus, an important strength of our work rests in the provision of the best possible synthesis of available evidence.
Cognitive impairment has emerged as a consistent target for drug and psychological treatments for BD. [76] [77] [78] Our results provide a rationale for testing the impact of those interventions in youths with BD. In addition, the impact of cognitive dysfunction in functioning among youths with BD remains largely unknown although a controlled study indicates that executive deficits may impair academic achievement in youths with BD. 
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Clinical guidance
• This meta-analysis indicates that euthymic youths with bipolar disorder exhibit impairments in global cognition, verbal and visual learning and memory, and working memory compared to healthy controls with moderate to large effect sizes.
• Neuropsychological assessments have varied across studies. In addition, the definition of euthymia was not consistent in included investigations. The impact of some illness variables (e.g. illness duration and number of previous affective episodes) on cognitive dysfunction in pediatric BD remains incompletely elucidated.
• Our findings indicate that cognitive dysfunction may be a viable therapeutic target for pharmacological and psychological intervention in euthymic youths with BD. 
